The increase in price target from $32 to $46 by Canaccord Genuity suggests a positive outlook on Staar Surgical's future performance, potentially leading to increased investor interest and a short-term positive impact on the stock price. However, the Hold rating indicates that the analyst believes the stock might not significantly outperform the market in the near term.